Shaperon Inc
Company Profile
Business description
Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient’s quality of life by developing safe and efficacious drugs and immunotherapies.
Contact
Gangnam Ace Tower G9
Suie 218 & 606, 174-10 Jagok-ro, Gangnam-gu
Seoul06373
KORT: +82 260838315
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
51
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,673.90 | 173.70 | -2.21% |
| CAC 40 | 7,017.50 | 257.45 | -3.54% |
| DAX 40 | 20,010.11 | 631.61 | -3.06% |
| Dow JONES (US) | 37,822.40 | 2,723.53 | -6.72% |
| FTSE 100 | 7,802.51 | 252.47 | -3.13% |
| HKSE | 20,354.44 | 2,495.37 | -10.92% |
| NASDAQ | 15,556.05 | 994.56 | -6.01% |
| Nikkei 225 | 33,141.70 | 638.88 | -1.89% |
| NZX 50 Index | 11,912.68 | 312.60 | -2.56% |
| S&P 500 | 5,041.94 | 32.14 | -0.63% |
| S&P/ASX 200 | 7,476.70 | 191.10 | -2.49% |
| SSE Composite Index | 3,114.20 | 17.62 | 0.57% |